Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid - A position paper developed by the European Consensus Panel on HDL-C

Current Medical Research and Opinion

Volumn 20, Issue 8, 2004, Pages 1253-1268

  Chapman, M John ^a   Assmann, Gerd ^b   Fruchart, Jean Charles ^c   Shepherd, James ^d   Sirtori, Cesare ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIV LILLE   (France)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Coronary heart disease; Diabetes; High density lipoprotein cholesterol; Metabolic syndrome; Treatment recommendations

Indexed keywords

ANTILIPEMIC AGENT; CLOFIBRATE; COLESTIPOL; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; SIMVASTATIN; STATINE DERIVATIVE; VERY LOW DENSITY LIPOPROTEIN;

ANGIOCARDIOGRAPHY; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG POTENCY; DRUG TARGETING; EDUCATION; FLUSHING; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 4344665253     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004402     Document Type: Review

References (113)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults [Adult Treatment Panel 111]. J Am Med Assoc 2001;285:2486-97
2. International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. http://www.athero.org. [Integrating the guidelines of the International Task Force for Prevention of Coronary Heart Disease, http://www.chd-taskforce.de/guidelines/toc.htm and the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (see reference 1)]
3. International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. http://www.athero.org. [Integrating the guidelines of the International Task Force for Prevention of Coronary Heart Disease, http://www.chd-taskforce.de/guidelines/toc.htm and the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (see reference 1)]
4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10
5. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med 2004;350:1495-504
6. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-900
7. Ballantyne CM, Olsson AG, Cook TJ, Mercuri M, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-51
8. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14
9. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl):S11-20
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. J Am Med Assoc 2002;287:356-9
11. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9
12. Health Survey for England 1998: cardiovascular disease. http://www.dh.gov.uk/Publications and Statistics/Published Survey/Health Survey for England/Health Survey Results/fs/en. [Accessed 5 April 2004]
13. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
14. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions. The Atherosclerosis Risk in Communities (ARIC) study. Circulation 2001;104:1108-13
15. Weverling-Rijnsburger AWE, Jonkers IJAM, van Exel E, Gussekloo J, Westendorp RGJ. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med 2003;163:1549-54
16. Pearson TA, Bulkley BH, Achuff SC, Kwiterovich PO, Gordis L. The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease. Am J Epidemiol 1979;109:285-95
17. Baldassarre D, Amato M, Pustina L, et al. Increased carotid artery intima-media thickness in subjects with primary hypoalphalipoproteinemia. Arterioscler Thromb Vasc Biol 2002:22:317-22
18. Miller M, Seidler A, Kwiterovich PO, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol. Circulation 1992;86:1165-70
19. Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994;35:871-82
20. Genest Jr JJ, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-33
21. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136-41
22. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9
23. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. J Am Med Assoc 1998;279:1615-22
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals. A randomised placebo-controlled trial. Lancet 2002;360:7-22
25. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New Engl J Med 1995;333:1301-7
26. Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999;99:736-43
27. Sacks FM. Clinical usefulness of HDL cholesterol as a target to lower risk of coronary heart disease. Summary of evidence and recommendations of an expert group. Br J Cardiol 2003;10:297-304
28. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975;231;360-81
29. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55
30. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18
31. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med 1990;323:1289-98
32. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J Am Med Assoc 1988;260:641-51
33. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl J Med 1999;341:410-8
34. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. J Am Med Assoc 2001;285:1585-91
35. Barzilai N, Atzmon G, Schechter EJ, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. J Am Med Assoc 2003;290:2030-40
36. De Grooth GT, Kuivenhoven JA, Stalenhoef AFH, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans. Circulation 2002;105:2159-65
37. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein. An initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004;24:490-7
38. Assmann G, Nofer J-R. Atheroprotective effects of high-density lipoproteins. Ann Rev Med 2003;54:321-41
39. Le Goff W, Guerin M, Chapman MJ. Pharmacological modulation of cholesteryl ester transfer protein: a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 2004;101:17-38
40. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999;100:594-8
41. Chiesa G, Monteggia E, Marchesi M, et al. Recombinant apolipoprotein A-I (Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002;90:974-80
42. Nissen SE, Tsunoda T, Tuzeu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. J Am Med Assoc 2003;290:2292-300
43. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins. Arterioscler Thromb Vasc Biol 2003;23:1724-31
44. 3. J Clin Invest 2004;113:569-81
45. Nofer J-R, Levkau B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 2001;276:34480-5
46. Spieker LE, Sudano I, Hurlimann D. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002;105:1399-402
47. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003;107:2944-8
48. Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001;103:108-12
49. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003;23:1881-8
50. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001;21:481-8
51. Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003;107:2775-9
52. Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 2003;171:87-96
53. Kuvin JT, Rämet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002;144:165-72
54. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004;67:411-9
55. Sacks FM, Pfeffer MA, Moyle LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996;335:1001-9
56. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349-57
57. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
58. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-Cholesterol. Benefit of pravastatin in diabetics and enhanced role for HDL-Cholesterol and triglycerides as risk factors. Circulation 2002;105:1424-8
59. Robins SJ, Rubins HB, Faas HF, et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26:1513-7
60. Boden WE, Pearson TA. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am J Cardiol 2000;85:645-50
61. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7
62. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985;110:1100-7
63. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16;434-44
64. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339:229-34
65. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-49
66. Pyorala K, Pedersen TR, Kjekshus J, Faedeman O, Olsson A, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patents with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20
67. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 1998;98:2513-9
68. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171:1-13
69. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10
70. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992;95:69-76
71. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164:697-705
72. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New Engl J Med 2001;345:1583-92
73. Canner PL, Furberg CD, McGovern ME. Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from the Coronary Drug Project. Circulation 2002;106(Suppl II):3138 [abstract]
74. Zhao X-Q, Morse J, Chait A, et al. Simvastatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome. J Am Coll Cardiol 2002;39(Suppl A):242A [abstract 1130-73]
75. Canner PL, Furberg CD, Terrin ML, McGovern ME. Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome: results from the Coronary Drug Project. J Am Coll Cardiol 2003;41 (Suppl A):291A [abstract]
76. Schaefer EJ, Lamon-Fava S, Cohn SD, et al. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 1994;35:779-92
77. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83-90
78. Davidson MH, Maki KC, Karp SK, Ingram KA. Management of hypercholesterolaemia in postmenopausal women. Drugs Aging 2002;19:169-78
79. Herrington DM, Reboussin DM, Brosniahan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. New Engl J Med 2000;343:522-9
80. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principle results from the Women's Health Initiative controlled trial. J Am Med Assoc 2002;288:321-3
81. Mostaghel E, Waters D. Women do benefit from lipid lowering: latest clinical trial data. Cardiol Rev 2003;11:4-12
82. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002;105:2962-7
83. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8500 men with coronary artery disease. [Department of Veterans Affairs HDL Intervention Trial Study Group]. Am J Cardiol 1995;75:1196-201
84. Genest Jr JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67;1185-9
85. Guérin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ. Proatherogenic role of elevated CE transfer from HDL to VLDL and dense LDL in type 2 diabetes. Impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001;21:282-8
86. Sacks FM and the Expert Group on HDL Cholesterol. The role of high-density lipoprotein cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139-42
87. The UK HDL-C Consensus Group. Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin 2004;20:241-7
88. Belalcazar LM, Ballantyne CM. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Prog Cardiovasc Dis 1998;41:151-74
89. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003;19:155-68
90. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995;16:5-13
91. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-5
92. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-104
93. Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195-202
94. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672-8
95. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003;91:1304-10
96. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82(Suppl 12A):74U-81U
97. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002;162:1568-76
98. Durrington P, Sniderman A. Hyperlipidaemia. Oxford Health Press; Oxford, 2000
99. Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease [review]. J Nutr Biochem 2003;14:298-305
100. Davidson MH. Combination therapy for dyslipidaemia: safety and regulatory considerations. Am J Cardiol 2002;90(Suppl):50K-60K
101. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737-43
102. Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001;87:476-9
103. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin [The Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation (ADVOCATE)]. Am J Cardiol 2003;91:667-72
104. McGovern ME, Malott CM, Stanek EJ, Simmons PD. Once-daily niacin extended-release is effective and safe for treatment of dyslipidemia associated with chronic kidney disease. J Am Coll Cardiol 2004;43(Suppl A):487A [abstract]
105. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(Suppl 1):S68-71
106. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672-93
107. Buchwald H, Campos C, Boen JR, et al. Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and met-analysis of lipid intervention trials: women in POSCH and other lipid trials. Ann Surg 1996;224:486-500
108. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104:2855-64
109. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. J Am Med Assoc 1990;264:723-6
110. McGovern ME. Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. Br J Diabetes Vasc Dis 2004;4:78-85
111. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. J Am Med Assoc 2000;284:1263-70
112. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression. Hepatic lipase-mediated changes in LDL density. Circulation 1999;99:1959-64
113. Gotto AM, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease. J Am Coll Cardiol 2004;43:717-24